It inhibits anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w, and unlike ABT 737, has shown single agent efficacy in numerous small cell lung carcinoma (SCLC) and leukemia/lymphoma cell lines [109-111]. Here, BCL2L1 is linked to lymphoma.